3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Completed
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Conditions
Neoplasms
8
Neoplasm Metastasis
8
Carcinoma, Non-Small-Cell Lung
8
Breast Neoplasms
8
Colorectal Neoplasms
7
Prostatic Neoplasms
6
Urinary Bladder Neoplasms
5
Leukemia, Myeloid, Acute
5
Squamous Cell Carcinoma of Head and Neck
4
Ovarian Neoplasms
4
Lung Neoplasms
4
Glioblastoma
4
Triple Negative Breast Neoplasms
3
Mouth Neoplasms
3
Head and Neck Neoplasms
3
Carcinoma, Transitional Cell
3
Carcinoma, Ovarian Epithelial
3
Uterine Cervical Neoplasms
2
Ureteral Neoplasms
2
Stomatitis
2
Recurrence
2
Oropharyngeal Neoplasms
2
Melanoma
2
Laryngeal Neoplasms
2
Gastrointestinal Neoplasms
2
Carcinoma, Renal Cell
2
Carcinoma
2
COVID-19
2
Brain Neoplasms
2
Adenocarcinoma
2
Interventions
Voriconazole
2
Caspofungin
2
telavancin
1
monalizumab
1
fludarabine phosphate
1
fish oil triglycerides
1
avdoralimab
1
Whole-Body Irradiation
1
Trimethoprim, Sulfamethoxazole Drug Combination
1
Therapeutics
1
Tacrolimus
1
Standard of Care
1
Sirolimus
1
Peripheral Blood Stem Cell Transplantation
1
Observation
1
Methotrexate
1
Melphalan
1
Interferon-gamma
1
Human Papillomavirus Recombinant Vaccine Quadrivalent, Types 6, 11, 16, 18
1
Hematopoietic Stem Cell Transplantation
1
Granulocyte Colony-Stimulating Factor
1
Filgrastim
1
Etoposide
1
Daptomycin
1
Cyclophosphamide
1
Clarithromycin
1
Bevacizumab
1
Antilymphocyte Serum
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 2
×
Infections
×
Standard of Care
×
Clear all
NCT04333914
2022-09-30
IMMUNONCOVID
Centre Leon Berard
Phase 2
Completed
19 enrolled